GUD.TO
Latest Trade
7.62CADChange
-0.06(-0.78%)Volume
116,804Today's Range
-
7.7352 Week Range
-
8.88As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 7.68 |
|---|---|
Open | 7.72 |
Volume | 116,804 |
3M AVG Volume | 5.93 |
Today's High | 7.73 |
Today's Low | 7.59 |
52 Week High | 8.88 |
52 Week Low | 7.10 |
Shares Out (MIL) | 135.63 |
Market Cap (MIL) | 1,033.49 |
Forward P/E | 43.46 |
Dividend (Yield %) | -- |
Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses
Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million
Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.
Industry
Biotechnology & Drugs
Executive Leadership
James C. Gale
Independent Chairman of the Board
Samira Sakhia
President, Chief Financial Officer, Director
Jonathan Ross Goodman
Chief Executive Officer, Director
Amal Khouri
Vice President - Business Development
Jody Engel
Director - Business Development
Price To Earnings (TTM) | 51.26 |
|---|---|
Price To Sales (TTM) | 73.41 |
Price To Book (MRQ) | 1.08 |
Price To Cash Flow (TTM) | 44.00 |
Total Debt To Equity (MRQ) | 0.10 |
LT Debt To Equity (MRQ) | 0.07 |
Return on Investment (TTM) | 2.15 |
Return on Equity (TTM) | 2.07 |
Canada's Knight Therapeutics Inc and shareholders of Biotoscana Investments expect to conclude transfer of control of the Latin American pharmaceutical company by Nov. 29, the latter said in a securities filing on Monday.
Knight Therapeutics <GUD.TO> will buy Brazilian pharmaceutical company Biotoscana Investments <GBIO33.SA> in a deal valued at 1.16 billion reais ($281 million) that will create a pharmaceutical platform in fast growing markets in Latin America.
Shares in Canada's Knight Therapeutics were up 9% in Toronto after the announcement of acquisition of Latin American pharmaceutical company Biotoscana Investments earlier on Monday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.